Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34684
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCon, Danny-
dc.contributor.authorSrinivasan, Ashish-
dc.date.accessioned2024-01-02T02:01:50Z-
dc.date.available2024-01-02T02:01:50Z-
dc.date.issued2024-01-
dc.identifier.citationAlimentary Pharmacology & Therapeutics 2024-01; 59(1)en_US
dc.identifier.issn1365-2036-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34684-
dc.language.isoeng-
dc.titleLetter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.affiliationGastroenterology and Hepatologyen_US
dc.identifier.affiliationDepartment of Medicine, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.en_US
dc.identifier.doi10.1111/apt.17770en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-4983-6103en_US
dc.identifier.pubmedid38085945-
dc.description.volume59-
dc.description.issue1-
dc.description.startpage140-
dc.description.endpage141-
dc.subject.meshtermssecondaryInfliximab/therapeutic use-
dc.subject.meshtermssecondaryColitis, Ulcerative/diagnosis-
dc.subject.meshtermssecondaryColitis, Ulcerative/drug therapy-
dc.subject.meshtermssecondaryAntibodies, Monoclonal, Humanized/therapeutic use-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptGastroenterology and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Oct 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.